Poseida Therapeutics (NASDAQ: PSTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.930 | ||||||
REV | 1.435M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Poseida Therapeutics (NASDAQ: PSTX) through any online brokerage.
Other companies in Poseida Therapeutics’s space includes: Graphite Bio (NASDAQ:GRPH), Jounce Therapeutics (NASDAQ:JNCE), Celcuity (NASDAQ:CELC), Immuneering (NASDAQ:IMRX) and Atossa Therapeutics (NASDAQ:ATOS).
The latest price target for Poseida Therapeutics (NASDAQ: PSTX) was reported by Piper Sandler on Friday, May 13, 2022. The analyst firm set a price target for 9.00 expecting PSTX to rise to within 12 months (a possible 309.09% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Poseida Therapeutics (NASDAQ: PSTX) is $2.2 last updated Today at June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Poseida Therapeutics.
Poseida Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Poseida Therapeutics.
Poseida Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.